Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Arbutus Biopharma Corporation
  6. Summary
    ABUS   CA03879J1003

ARBUTUS BIOPHARMA CORPORATION

(ABUS)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
2.930 USD   +2.09%
01/05Arbutus Biopharma : Corporate Presentation - January 2023
PU
01/05Arbutus Biopharma Corp : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/05Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2023 01/23/2023 01/24/2023 01/25/2023 01/26/2023 Date
2.76(c) 2.76(c) 2.78(c) 2.87(c) 2.93(c) Last
619 003 380 625 308 902 1 409 120 410 353 Volume
+4.55% 0.00% +0.72% +3.24% +2.09% Change
More quotes
Estimated financial data (e)
Sales 2022 52,5 M 39,3 M 39,3 M
Net income 2022 -90,7 M -67,9 M -67,9 M
Net Debt 2022 - - -
P/E ratio 2022 -6,43x
Yield 2022 -
Sales 2023 28,9 M 21,7 M 21,7 M
Net income 2023 -117 M -87,4 M -87,4 M
Net Debt 2023 - - -
P/E ratio 2023 -5,12x
Yield 2023 -
Capitalization 616 M 461 M 461 M
Capi. / Sales 2022 11,7x
Capi. / Sales 2023 21,3x
Nbr of Employees 86
Free-Float 74,2%
More Financials
Company
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor,... 
Read more
Sector
Pharmaceuticals
Calendar
03/09Earnings Release
More about the company
Ratings of Arbutus Biopharma Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ARBUTUS BIOPHARMA CORPORATION
01/05Arbutus Biopharma : Corporate Presentation - January 2023
PU
01/05Arbutus Biopharma Corp : Results of Operations and Financial Condition, Other Events, Fina..
AQ
01/05Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
GL
2022Arbutus Biopharma : Corporate Presentation - December 2022
PU
2022Arbutus Biopharma Says Data Reinforces Antigen-Reducing Capacity of Chronic Hepatitis B..
MT
2022Arbutus Biopharma Corp : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Th..
GL
2022Arbutus Biopharma Corporation Completes Enrollment in its Phase 2a Clinical Trial Combi..
CI
2022HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy..
MT
2022ARBUTUS BIOPHARMA CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
2022Transcript : Arbutus Biopharma Corporation, Q3 2022 Earnings Call, Nov 09, 20..
CI
2022Arbutus Biopharma : Corporate Presentation - November 2022
PU
2022Arbutus : Q3 Earnings Snapshot
AQ
2022Arbutus Biopharma Corp : Results of Operations and Financial Condition, Other Events, Fina..
AQ
2022Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $6M, vs. Street Es..
MT
More news
News in other languages on ARBUTUS BIOPHARMA CORPORATION
2022Arbutus Biopharma déclare que les données renforcent la capacité de réduction de l'anti..
2022Arbutus Biopharma Corporation achève le recrutement dans son essai clinique de phase 2a..
2022Arbutus Biopharma Corporation annonce ses résultats pour le troisième trimestre et les ..
2022Arbutus Biopharma Corporation présente les données cliniques du AB-729 et les données p..
2022Arbutus Biopharma Corporation nomme Mike Mcelhaugh au poste de directeur de l'exploitat..
More news
Analyst Recommendations on ARBUTUS BIOPHARMA CORPORATION
More recommendations
ETFs positioned on ARBUTUS BIOPHARMA CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.51%2.66%United_States
ETFMG Treatments Testing and Advancements E...0.38%-0.14%-NC
ALPS Medical Breakthroughs ETF - USD0.25%2.43%United_States
IShares Micro-Cap ETF - USD0.07%0.02%United_States
Invesco Nasdaq Biotechnology ETF - USD0.03%0.87%-United_States
More ETFs positioned on ARBUTUS BIOPHARMA CORPORATION
Analysis
Arbutus files patent infringement lawsuit against Moderna related to COVID shot
Chart ARBUTUS BIOPHARMA CORPORATION
Duration : Period :
Arbutus Biopharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARBUTUS BIOPHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,91 CAD
Average target price 7,27 CAD
Spread / Average Target 85,7%
EPS Revisions
Managers and Directors
William H. Collier President, Chief Executive Officer & Director
David C. Hastings Chief Financial & Accounting Officer
Frank M. Torti Chairman
Michael J. Sofia Chief Scientific Officer
Michael J. McElhaugh Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ARBUTUS BIOPHARMA CORPORATION23.18%461
CSL LIMITED2.91%101 057
SAMSUNG BIOLOGICS CO.,LTD.-3.17%45 947
BIOGEN INC.5.57%42 097
WUXI BIOLOGICS (CAYMAN) INC.19.21%38 495
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.07%24 671